Andere Sprachen Virax Biolabs Group Limited

Aktien

A3E2F1

KYG9495L1251

VRAX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:01 03.05.2024			% 5 Tage	% 1. Jan.
0,6139 ^USD	+0,64 %		-11,03 %	-57,95 %

25.04.	Virax Biolabs stellt auf der ESCMID Global 2024 ein Portfolio von Lösungen für das Immunprofiling zur Bewertung der adaptiven Immunität bei postviralen Syndromen vor	CI
12.01.	Virax Biolabs Group Limited berichtet über die Ergebnisse für das Halbjahr bis zum 30. September 2023	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Virax Biolabs : Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024 - Form 6-K	25.04.
Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024	25.04.
Virax Biolabs to Participate at ESCMID Global 2024	17.04.
Virax Biolabs : to Participate at ESCMID Global 2024 - Form 6-K	16.04.
Virax Biolabs : Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency - Form 6-K	15.03.
Virax Biolabs Group Limited Reports Earnings Results for the Half Year Ended September 30, 2023	12.01.
Virax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients	22.12.
Virax Biolabs Group Limited Forges Strategic Research Collaboration with University of Manchester and Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients	21.12.
Virax Biolabs Group Limited Announces 1-for-10 Share Consolidation	15.12.
Top Premarket Gainers	12.12.
Virax Biolabs : Notice of 2023 Annual General Meeting of Shareholders To Be Held on - Form 6-K	08.11.
Virax Biolabs : CLAWBACK POLICY - Form 6-K	31.10.23
Virax Biolabs Group Limited announced that it has received $2.15 million in funding	17.10.23
Virax Biolabs Group Limited announced that it expects to receive $2.15 million in funding	12.10.23
Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar	13.09.23
Virax Biolabs : Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar - Form 6-K	12.09.23
Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum	04.09.23
Virax Biolabs Group Names Nigel McCracken Operating Chief.	01.09.23
Virax Biolabs Group Limited Announces Management Changes	01.09.23
Nasdaq Approves 180-Day Extension for Virax Biolabs Group to Meet Minimum $1 Bid	04.08.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Virax Biolabs Group Limited

Aktien

A3E2F1

KYG9495L1251

VRAX

Andere Sprachen

Filter